| Population 2016 |
11 million |
| |
| | | | | |
| Estimates of TB burden*, 2016 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
2 |
(1.2–3.1) |
19 |
(12–29) |
| Mortality (HIV+TB only) |
0.52 |
(0.33–0.75) |
4.9 |
(3.1–7.1) |
| Incidence (includes HIV+TB) |
12 |
(8–18) |
118 |
(76–169) |
| Incidence (HIV+TB only) |
1.5 |
(0.96–2.2) |
14 |
(9.1–20) |
| Incidence (MDR/RR-TB)** |
0.42 |
(0.27–0.58) |
4 |
(2.5–5.5) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2016 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0.66 |
(0.4–0.91) |
4.2 |
(2.5–5.8) |
4.8 |
(2.9–6.7) |
| Males |
0.75 |
(0.46–1) |
6.8 |
(4.2–9.5) |
7.6 |
(4.6–11) |
| Total |
1.4 |
(0.86–2) |
11 |
(6.7–15) |
12 |
(8–18) |
| |
| | | | | |
| TB case notifications, 2016 |
|
| Total cases notified |
7 662 |
| Total new and relapse |
7 567 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
96% |
| - % pulmonary |
73% |
| - % bacteriologically confirmed among pulmonary |
83% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2016 |
61% (43–94) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 |
0.21 (0.11–0.33) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2016 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
877 |
12% |
| - on antiretroviral therapy |
795 |
91% |
| |
| | | | | |
| Drug-resistant TB care, 2016 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
200
(160–230) |
| Estimated % of TB cases with MDR/RR-TB |
2.8% (2.1–3.4) |
13% (8.9–17) |
|
| % notified tested for rifampicin resistance |
5% |
64% |
615 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
52 |
| Laboratory-confirmed cases |
MDR/RR-TB: 80, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 80, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2015 |
92% |
6 892 |
| Previously treated cases, excluding relapse, registered in 2015 |
83% |
77 |
| HIV-positive TB cases registered in 2015 |
87% |
907 |
| MDR/RR-TB cases started on second-line treatment in 2014 |
90% |
41 |
| XDR-TB cases started on second-line treatment in 2014 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2016 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
33% (31–37) |
| |
| | | | | |
| TB financing, 2017 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed | | |
| | | | | |